OncoTartis

About OncoTartis

OncoTartis, Inc. is a private biotechnology company founded in 2011, originating from Prof. Andrei's laboratory at Roswell Park Cancer Institute in Buffalo, NY. The company specializes in developing a novel category of anti-cancer drugs that target tissue-specific vulnerabilities in various cancers, including breast, prostate, ovarian, melanoma, and hematological malignancies. OncoTartis employs a proprietary drug discovery approach known as TARTIS (TARgeting TISsue), designed to create small molecules for treating malignancies. The company's leading product, OT 82, is a nicotinamide phosphoribosyltransferase (NAMPT) inhibitor aimed at treating hematological malignancies. OncoTartis primarily serves the oncology market, focusing on patients suffering from specific types of cancer. The business model revolves around drug development and commercialization, generating revenue through the sale and licensing of its proprietary treatments.